the prostaglandins (PGs). Chase & Aurbach (1970) first showed that PGF2z, stimulated bone cyclic adenosine monophosphate (AMP) production whilst Klein & Raisz (1970) showed that PGs were potent bone resorbing agents in tissue culture. Evidence for a role of PGs in the hypercalcaemia of cancer came from the work of Tashjian et al. (1972) who found that a mouse fibrosarcoma in tissue culture produced a bone resorbing agent which could be identified as PGE2. The purpose of this present paper is to review some of the current hypotheses concerning the role of PGs in the physiology and pathophysiology of bone resorption.
Hypercalcaemic cancer in experimental animals Most of the information concerning the production of PGs as bone resorbing agents by cancers has come from animals bearing hypercalcaemia-producing tumours such as the HSDM1 fibrosarcoma in mice, Walker tumour in rats and the VX2 carcinoma in rabbits. The mouse fibrosarcoma produces hypercalcaemia about 21 weeks after implantation (Tashjian et al. 1972) , and this can be prevented by treatment of the animals with indomethacin (a PG synthetase inhibitor) (Tashjian et al. 1972) or hydrocortisone (Tashjian, Voekkel & Levine 1977) . Moreover, when tumour cells were grown in monolayer culture, the supernatant medium was found to contain bone resorbing activity which was not present when cells were grown in the presence of indomethacin (Tashjian et al. 1972) . Essentially similar studies have been performed using the VX2 carcinoma (Tashjian et al. 1973 ) and the Walker tumour in rats (Powles et al. 1973) leading to the conclusion that PGE2 is the major cause of increased bone destruction by these tumours. In spite of this evidence it has been difficult to show that circulating levels of PGE2 are increased in malignant hypercalcaemia (Tashjian et al. 1972 (Tashjian et al. , 1973 , and intravenous infusion of relatively high concentrations of PGE2 does not produce hypercalcaemia (Beliel et al. 1973 , Robinson & Parsons 1975 . However, PGE2 is rapidly cleared from the circulation and converted to 13,14-dihydro-15-keto PGE2 (Figure 1) Figure 1 . The metabolism of PGE2 in man using the mouse fibrosarcoma model, have found that plasma levels of this metabolite were elevated some 10-fold before hypercalcaemia developed, whilst PGE2 levels were only minimally increased. It therefore seems likely that the rate of production of PGE2 is rather more important than the absolute plasma levels reached, hence constantly exposing the bone cells to increased amounts of PGE2.
An alternative view would be that marked hypercalcaemia only develops once tumour cells have invaded bone. The VX2 carcinoma presented a suitable model to test this hypothesis since, when cells are injected intramuscularly, tumour deposits can be found in bone after a latent period. Indomethacin readily prevents the development of hypercalcaemia (Tashjian et al. 1973) . Galasko & Bennett (1976) have shown that when the tumour was injected into the bone marrow there was a rapid increase in the number of osteoclasts (bone resorbing cells) near the site of tumour injection and, furthermore, that when rabbits were treated with indomethacin the increase in osteoclast count following tumour injection was less.
Thus, it is possible to propose a model whereby a PG, probably PGE2, can be responsible for bony destruction in both primary and metastatic disease. If PG production by the primary tumour is markedly increased, although plasma levels are only slightly elevated, this increase will be sufficient to cause a small increase in bone resorption, possibly due to osteoclast activation. This will cause the production of microscopic resorption cavities in bone which will represent suitable sites for the development of bony metastases. Once tumour cells have spread to bone then the large local increase in PG levels will stimulate further increases in bone destruction leading to the development of gross hypercalcaemia (Figure 2 (Robertson et al. 1975 , Demers et al. 1977 , but there are data to show that the urinary excretion of PGE-M is increased in hypercalcaemic cancer (Seyberth et al. 1975 ). However, attempts to treat the hypercalcaemia with indomethacin have not fulfilled their promise (Coombes et al. 1976) . Nevertheless, it is important to be able to predict those patients who, although normocalcaemic at surgery, may later develop bony metastases. Powles et al. (1973) showed that when fragments of human breast carcinomata were cocultured with bone, resorption occurred. Inclusion of indomethacin in culture media could prevent the resorption and, on the basis of radioimmunoassay studies, it was later suggested that the bone resorption was due to PGE2 (Dowsett et al. 1976 ). Bennett et al. (1975) found that when PG production by breast tumours in short-term culture was high, the same patients subsequently were found to develop bony metastases. Bennett et al. (1975) made the suggestion that the bone resorbing factor was PGF2,, although this appears unlikely in view of the relative low bone resorbing activity of PGF2, (Dietrich et al. 1975 ). We have carried out similar studies but our data suggest that the incidence of production of bone resorbing factors by breast tumours is lower than that suggested by Powles et al. (1973) . However, all such studies suggest a potential value of such systems in evaluating the potential production of bone resorbing agents by tumours.
Coincubation studies of fragments of human renal cortical carcinoma (hypernephroma) tissue with bone have been performed. This tumour has been reported to be associated with hypercalcaemia and with the ectopic production of PTH (Greenberg et al. 1973) . The cells of the tumour have ultrastructural similarities to cells of normal proximal or distal tubules (Hunt et al. 1978) , and it is possible at surgery to obtain control unaffected renal tissue. It has been shown that there is an increase in adenylate cyclase activity in tumour cell membranes compared to control tissue (Hunt et al. 1978) and this is reflected by a higher level of cyclic AMP in the renal vein than artery in the patients at surgery. It was suggested that this derangement of adenylate cyclase could be concerned with metabolic or differentiated functions of the tumour cells. Because of the association between this tumour and hypercalcaemia, the potential production of bone resorbing factors by this tumour was investigated.
Using the coculture system we have shown that a number of renal cortical carcinomata do produce a bone resorbing factor which by a variety of criteria can be identified as a prostaglandin (probably PGE2) (Atkins, Ibbotson et al. 1977) . A typical case is shown in Figure 3 , where it can be seen that the tumour explants caused bone resorption which was inhibited when indomethacin was included in the culture medium. Inclusion of theophylline (a cyclic AMP phosphodiesterase inhibitor) led to an enhancement of bone resorption. Direct measurement of PGE by radioimmunoassay helps confirm that the bone resorbing factor is indeed PGE. Studies using theophylline provide a clue to the possible significance of the increased adenylate cyclase activity. It is likely that the increased rate of cyclic AMP production may act to stimulate the synthesis of PGs which in turn could have a variety of metabolic effects on bone resorption. Furthermore, it is possible that, because PGE2 itself can stimulate adenylate cyclase, the system is self-perpetuating, that is, there is a continued drive to produce PGE2 (Figure 4 ). Such possibilities have been investigated by incubation of fragments of normal rat kidney with '4C-arachidonic acid and isolating the PGs formed. Table 2 shows that both theophylline and dibutyryl cyclic AMP enhance the metabolism of arachidonic acid to PGs.
What we cannot define from these studies is whether bone resorption is the specific function of the PG production by the renal tumour cells. It is quite possible that increased adenylate cyclase activity and PG production may be associated with disturbances in the production of other hormones such as erythropoietin (Greaves et al. 1977) The role of prostaglandins in normal bone metabolism The fact that PGs may cause the hypercalcaemia in cancer strongly suggests that they play a part in normal bone metabolism, but this aspect of bone physiology has received little attention. It is accepted that PGE2 is the most potent bone resorbing PG in tissue culture (Dietrich et al. 1975) and that, in several respects, its action is similar to that of PTH in that it stimulates cyclic AMP production (Chase & Aurbach 1970) and inhibits collagen synthesis (Raisz & Koolemans-Beynen 1974) . Since PGs usually act relatively close to their site of action it is essential that, if they are to play an important role in bone metabolism, they should be produced locally by bone cells. This possibility has not been investigated.
In an attempt to investigate further the effects of PGs on bone and bone cells we have used cells from a 32P-induced transplantable osteogenic sarcoma in the rat. These tumours and their cells have a pattern of hormonal responsiveness which is very similar to that of normal bone cells (Martin et al. 1976 , Atkins, Hunt et al. 1978 . In particular, the ability of various PGs to stimulate cyclic AMP formation ) exactly parallels their in vitro bone resorbing activity (Tashjian, Tice & Sides 1977 , Raisz et al. 1977 . Furthermore, these hormonally responsive cells offer a unique opportunity to study the actions of other short-lived prostaglandin-like substances which would be almost impossible to test in more conventional bone systems.
Prostaglandin biosynthesis and metabolism is very complex. The biosynthesis pathways are outlined in Figure 4 . Briefly, after the formation of an obligatory cyclic endoperoxide intermediate PG biosynthesis can follow one or more alternative pathways. First, there is the formation of biologically inactive hydroxyacids. Secondly, the endoperoxides can be converted to almost any of the conventional PGs all with somewhat varying biological activities, or to short-lived compounds-thromboxane A2 and prostacyclin (PGI2). The role of these compounds is only understood well in the blood platelet. Thromboxane A2 is a potent aggregatory agent produced by the platelet, whilst prostacyclin is a very potent antiaggregatory agent produced in the arterial walls (Hamberg et al. 1975 , Gryglewski et al. 1976 ). Dietrich et al. (1975) Many other tissues produce thromboxane A2 and prostacyclin, which may represent the true local regulatory PGs. The cyclic endoperoxides themselves will stimulate platelet aggregation (Hamberg et al. 1975) . In conventional bone culture systems there is no convincing evidence for a bone resorbing effect (Raisz et al. 1977 ). However, due to their relative instability it is generally necessary to use stable analogues of these compounds. Two such analogues are known (containing an epoxymethano linkage, U44069 & U46619). These analogues do not have significant bone resorbing effects and are only weak stimulators of cyclic AMP formation in osteogenic sarcoma cells (Table 3 ). It has not been possible to test the effect of prostacyclin in any bone system, but it might be predicted that it would be a potent stimulator of cyclic AMP production in the osteogenic sarcoma cells. None of the known major PGE2 metabolites are as effective stimulators of bone resorption in tissue culture as PGE2 (Tashjian, Tice & Sides 1977 , Raisz et al. 1977 , nor do they, except at high doses, stimulate cyclic AMP formation in osteogenic sarcoma cells ( Figure 5 ) . These data allow the inference that, although it is easy to demonstrate an increase in circulating levels of PG metabolites in hypercalcaemic cancer, the bone resorption occurring is due either to PGE2 itself or to a shortlived PG intermediate such as thromboxane A2 or prostacyclin.
Several groups of workers have suggested that the action of thyroid stimulating hormone (TSH) is via a stimulation of PGE2 synthesis in thyroid membranes and that, in turn, PGE2 stimulates cyclic AMP production and hence thyroid secretion (Sato et al. 1972) . We have evidence to suggest that PGE2 is not involved in the action of PTH on osteogenic sarcoma cells. During the enzymic dispersion of isolated cells there is a selective loss of responsiveness to PTH but not to PGE Figure 5 . Pathways for the biosynthesis of prostaglandins from arachidonic acid evidence is that PG antagonists (SC-19220 and 7-oxa-1 3-prostynoic acid) selectively antagonize the action of PGE2 (Waller et al. 1979) . Thus it is possible to suggest that the action of PGE2 (or other PG-like substances) is independent of PTH action, at least in these tumour cells which are closely related to bone. It seems very unlikely that PG effects on bone are mediated by peripherally-produced PGs and it is necessary to consider whether PGs can play a local role in the regulation of bone turnover. This role is particularly hard to define, but remembering the local regulatory effects of PGs in the platelet, it is possible that a PG plays an important role in the minute-to-minute regulation of bone turnover. In the absence of any apparent stimulation, for example in hypoparathyroidism, there is a remarkable degree of self-regulation in bony tissue -a possible role for prostaglandins?
Conclusions
Although there is ample evidence that PGs are important in the pathogenesis of hypercalcaemia (bone destruction) in cancer, the role of PGs in normal bone metabolism is poorly understood. However, it is anticipated that PGs may play a central role in the control of bone turnover and possibly in the minute-to-minute regulation of plasma calcium.
